| Popis: |
Andrea Rossi,1 Bojana Butorac-Petanjek,2 Marco Chilosi,3 Borja G Cosío,4 Matjaz Flezar,5 Nikolaos Koulouris,6 José Marin,7 Neven Miculinic,2 Guido Polese,8 Miroslav Samaržija,9 Sabina Skrgat,5 Theodoros Vassilakopoulos,10 Andrea Vukić-Dugac,9 Spyridon Zakynthinos,10 Marc Miravitlles11 1Pulmonary Unit, University of Verona, Verona, Italy; 2Respiratory Department, University Hospital Centre, Zagreb, Croatia; 3Pathology Unit, University of Verona, Verona, Italy; 4Department of Respiratory Medicine, Hospital Son Espases-IdISPa and CIBERES, Palma, Spain; 5University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia; 6First Department of Respiratory Medicine, Medical School of National and Kapodistrian University of Athens, Greece; 7Respiratory Medicine, Hospital Universitario Miguel Servet, CIBERES & IISAragon, Zaragoza, Spain; 8Pulmonary Unit, ULSS 22 Bussolengo, Italy; 9Jordanovac Department for Respiratory Diseases, University of Zagreb School of Medicine, University Hospital Centre, Zagreb, Croatia; 10First Department of Critical Care and Pulmonary Services, Evangelismos Hospital, University of Athens, Greece; 11Pneumology Department, Hospital Universitary Vall d’Hebron, Barcelona, Spain Abstract: Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and morbidity worldwide, with high and growing prevalence. Its underdiagnosis and hence undertreatment is a general feature across all countries. This is particularly true for the mild or early stages of the disease, when symptoms do not yet interfere with daily living activities and both patients and doctors are likely to underestimate the presence of the disease. A diagnosis of COPD requires spirometry in subjects with a history of exposure to known risk factors and symptoms. Postbronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity |
